MFN News Items | Nanologica

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

30 January, 2026

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till extra bolagsstämma onsdagen den 4 mars 2026, klockan 10.00, i Advokatfirman Lindahls lokaler, på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i bolagsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 24 februari 2026, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast torsdagen den 26

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

30 January, 2026

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby invited to attend the Extraordinary General Meeting to be held on Wednesday, March 4, 2026, at 10.00 a.m. CET at Advokatfirman Lindahl's premises, at Smålandsgatan 16, Stockholm. Right to participate in the meeting Shareholders who wish to participate in the Extraordinary General Meeting must: be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on Tuesday,

NANOLOGICA GENOMFÖR RIKTADE EMISSIONER OM TOTALT CIRKA 13,7 MSEK SAMT EN FULLT SÄKERSTÄLLD FÖRETRÄDESEMISSION OM CIRKA 82,5 MSEK

30 January, 2026

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN DISTRIBUTION KRÄVER PROSPEKT, REGISTRERING ELLER ANDRA ÅTGÄRDER UTÖVER DE SOM FÖLJER AV SVENSK RÄTT, ÄR FÖRBJUDEN, ELLER ANNARS STRIDER MOT TILLÄMPLIGA REGLER I SÅDAN JURISDIKTION ELLER INTE KAN SKE UTAN TILLÄMPNING AV UNDANTAG FRÅN SÅDAN ÅTGÄRD. SE AVSNITTET "VIKTIG INFORMATION" I SLUTET

NANOLOGICA CARRIES OUT DIRECTED SHARE ISSUES OF APPROX. SEK 13.7 MILLION IN TOTAL, AND A FULLY SECURED RIGHTS ISSUE OF APPROX. SEK 82.5 MILLION

30 January, 2026

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION REQUIRES A PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRAVENES APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH

Nanologica AB (publ) förvärvar Ardena Södertälje AB

29 January, 2026

Nanologica AB (publ) (”Nanologica”) har idag ingått avtal om och genomfört förvärv av samtliga aktier i Ardena Södertälje AB (”Syntagon”) från Ardena Sweden (”Säljaren”). Köpeskillingen uppgår till ca 8,6 MSEK och erläggs i form av nyemitterade aktier i Nanologica. Syntagon är en Contract Development and Manufacturing Organization med drygt 45 anställda som under 2025 omsatte ca 80 MSEK. Nanologica gör bedömningen att förvärvet kommer att bidra positivt till koncernens resultat redan under 2026. Förvärvet stärker

Nanologica AB (publ) Acquires Ardena Södertälje AB

29 January, 2026

Nanologica AB (publ) ("Nanologica") has today entered into an agreement and completed the acquisition of all shares in Ardena Södertälje AB ("Syntagon") from Ardena Sweden (the "Seller"). The purchase price amounts to approximately SEK 8.6 million and will be paid in the form of newly issued shares in Nanologica. Syntagon is a Contract Development and Manufacturing Organization with just over 45 employees, which in 2025 had sales of approximately SEK 80 million. Nanologica believes that

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.